118 related articles for article (PubMed ID: 16122707)
21. Bis-imidazoles as molecular probes for peripheral sites of the zinc endopeptidase of botulinum neurotoxin serotype A.
Merino I; Thompson JD; Millard CB; Schmidt JJ; Pang YP
Bioorg Med Chem; 2006 May; 14(10):3583-91. PubMed ID: 16458011
[TBL] [Abstract][Full Text] [Related]
22. [Mechanisms of action of botulinum toxins and neurotoxins].
Poulain B; Lonchamp E; Jover E; Popoff MR; Molgó J
Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S73-6. PubMed ID: 19576489
[TBL] [Abstract][Full Text] [Related]
23. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin.
Garcia-Rodriguez C; Levy R; Arndt JW; Forsyth CM; Razai A; Lou J; Geren I; Stevens RC; Marks JD
Nat Biotechnol; 2007 Jan; 25(1):107-16. PubMed ID: 17173035
[TBL] [Abstract][Full Text] [Related]
24. [Screening of botulinum neurotoxin type A-binding peptides by phage display peptide library].
Shi J; Wang H; Yin J; Hou XJ
Wei Sheng Wu Xue Bao; 2006 Feb; 46(1):136-8. PubMed ID: 16579481
[TBL] [Abstract][Full Text] [Related]
25. Novel inhibitors of botulinus neurotoxin "A" based on variations of the SNARE motif.
Hayden J; Pires J; Hamilton M; Moore G
Proc West Pharmacol Soc; 2000; 43():71-4. PubMed ID: 11056961
[No Abstract] [Full Text] [Related]
26. Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding.
Burnett JC; Schmidt JJ; McGrath CF; Nguyen TL; Hermone AR; Panchal RG; Vennerstrom JL; Kodukula K; Zaharevitz DW; Gussio R; Bavari S
Bioorg Med Chem; 2005 Jan; 13(2):333-41. PubMed ID: 15598556
[TBL] [Abstract][Full Text] [Related]
27. Molecular characterization of the protease from Clostridium botulinum serotype C responsible for nicking in botulinum neurotoxin complex.
Suzuki T; Yoneyama T; Miyata K; Mikami A; Chikai T; Inui K; Kouguchi H; Niwa K; Watanabe T; Miyazaki S; Ohyama T
Biochem Biophys Res Commun; 2009 Feb; 379(2):309-13. PubMed ID: 19103155
[TBL] [Abstract][Full Text] [Related]
28. [Tetanus and botulinum toxins are zinc metallopeptidases: molecular mechanisms and inhibition of their neurotoxicity].
Cornille F; Roques BP
J Soc Biol; 1999; 193(6):509-16. PubMed ID: 10783709
[TBL] [Abstract][Full Text] [Related]
29. Immune recognition of BoNTs A and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action.
Atassi MZ
Toxicon; 2009 Oct; 54(5):600-13. PubMed ID: 19285100
[TBL] [Abstract][Full Text] [Related]
30. mRNA-display-based selections for proteins with desired functions: a protease-substrate case study.
Valencia CA; Cotten SW; Dong B; Liu R
Biotechnol Prog; 2008; 24(3):561-9. PubMed ID: 18471027
[TBL] [Abstract][Full Text] [Related]
31. Pharmacophore-guided lead optimization: the rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease.
Burnett JC; Wang C; Nuss JE; Nguyen TL; Hermone AR; Schmidt JJ; Gussio R; Wipf P; Bavari S
Bioorg Med Chem Lett; 2009 Oct; 19(19):5811-3. PubMed ID: 19703771
[TBL] [Abstract][Full Text] [Related]
32. Ribosome display selection of a metal-binding motif from an artificial peptide library.
Wada A; Sawata SY; Ito Y
Biotechnol Bioeng; 2008 Dec; 101(5):1102-7. PubMed ID: 18613123
[TBL] [Abstract][Full Text] [Related]
33. When the surface tells what lies beneath: combinatorial phage-display mutagenesis reveals complex networks of surface-core interactions in the pacifastin protease inhibitor family.
Szenthe B; Patthy A; Gáspári Z; Kékesi AK; Gráf L; Pál G
J Mol Biol; 2007 Jun; 370(1):63-79. PubMed ID: 17499271
[TBL] [Abstract][Full Text] [Related]
34. Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations.
Capková K; Hixon MS; McAllister LA; Janda KD
Chem Commun (Camb); 2008 Aug; (30):3525-7. PubMed ID: 18654701
[TBL] [Abstract][Full Text] [Related]
35. Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F.
Schmidt JJ; Stafford RG
Appl Environ Microbiol; 2003 Jan; 69(1):297-303. PubMed ID: 12514008
[TBL] [Abstract][Full Text] [Related]
36. A graphene oxide based fluorescence resonance energy transfer (FRET) biosensor for ultrasensitive detection of botulinum neurotoxin A (BoNT/A) enzymatic activity.
Shi J; Guo J; Bai G; Chan C; Liu X; Ye W; Hao J; Chen S; Yang M
Biosens Bioelectron; 2015 Mar; 65():238-44. PubMed ID: 25461164
[TBL] [Abstract][Full Text] [Related]
37. Selection of peptide inhibitors against the Pseudomonas aeruginosa MurD cell wall enzyme.
Paradis-Bleau C; Beaumont M; Boudreault L; Lloyd A; Sanschagrin F; Bugg TD; Levesque RC
Peptides; 2006 Jul; 27(7):1693-700. PubMed ID: 16517013
[TBL] [Abstract][Full Text] [Related]
38. Phage display screening against a set of targets to establish peptide-based sugar mimetics and molecular docking to predict binding site.
Yu L; Yu PS; Yee Yen Mui E; McKelvie JC; Pham TP; Yap YW; Wong WQ; Wu J; Deng W; Orner BP
Bioorg Med Chem; 2009 Jul; 17(13):4825-32. PubMed ID: 19447041
[TBL] [Abstract][Full Text] [Related]
39. A cyclic peptide-polymer probe for the detection of Clostridium botulinum neurotoxin serotype A.
Ma H; Zhou B; Kim Y; Janda KD
Toxicon; 2006 Jun; 47(8):901-8. PubMed ID: 16730044
[TBL] [Abstract][Full Text] [Related]
40. Use of phage display and polyvalency to design inhibitors of protein-protein interactions.
Mourez M; Collier RJ
Methods Mol Biol; 2004; 261():213-28. PubMed ID: 15064461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
